Renal Ultrastructural and Biochemical Injuries Induced by Aminoglycosides

by Constantin Cojocel,* N. Docius,† Keizo Maita,* Jacqueline H. Smith* and Jerry B. Hook*

Aminoglycoside-induced proteinuria may result from general renal damage or may reflect alterations in specific steps in the renal handling of proteins. To differentiate between the two possibilities, experiments were designed to quantify the effects of nephrotoxic doses of gentamicin, tobramycin and netilmicin in the intact rat, isolated perfused rat kidney (IPK) and kidney slices using the cationic low molecular weight protein lysozyme as a model protein. Each aminoglycoside was administered IP to male Wistar rats (15 or 30 mg/kg/day) for 5 or 7 days.

Scanning and transmission electron microscopy indicated that gentamicin and tobramycin induced a decrease in the number and diameter of endothelial fenestrae and degranulation of the myoepithelioid cells of the juxtaglomerular apparatus. Concurrently, gentamicin and tobramycin decreased the glomerular sieving coefficient of lysozyme from 0.8 to 0.6 and 0.5, respectively. Netilmicin did not affect the percentage reabsorption of lysozyme whereas gentamicin and tobramycin induced a 50% decrease in lysozyme reabsorption by the IPK. Gentamicin and tobramycin decreased equally lysozyme degradation by the IPK; this decrease was time- and dose-dependent when evaluated in slices from renal cortex. Perfusion of rat kidneys with gentamicin induced a dose-dependent decrease in reabsorption and catabolism of lysozyme.

In conclusion, these studies demonstrate that polycationic aminoglycosides alter ultrastructure and glomerular permeability, tubular reabsorption and intracellular digestion of proteins.

Aminoglycoside antibiotics are valuable therapeutic agents which are employed frequently in clinical management of gram-negative bacterial infections. Nephrotoxicity, a major side effect of aminoglycoside treatment, is usually characterized by a fall in glomerular filtration rate (GFR), decreased urinary concentrating capacity, proteinuria, enzymuria and ultrastructural alteration of proximal tubular cells. For several years, efforts of various research groups have focused on detection and assessment of the mechanisms of aminoglycoside nephrotoxicity. Luminal uptake is the major route of aminoglycoside tubular reabsorption and subsequent intracellular accumulation (1–3). Contraluminal uptake of aminoglycosides (4,5) also appears to contribute to the accumulation of aminoglycosides. Although aminoglycosides inhibit Na, K-ATPase activity, it is unlikely that this is the primary mechanism of aminoglycoside nephrotoxicity (6). The effects of aminoglycosides on mitochondrial, (7) and lysosomal function (8–11) appear to play the main role in aminoglycoside-induced nephrotoxicity. There is new evidence to support glomerular alterations induced by aminoglycosides (8), though this is still disputed (12–14). Low molecular weight proteins (LMWP) are well filtered by the glomerulus and almost totally reabsorbed by the tubule in control conditions. Renal handling of LMWP such as lysozyme and β2-microglobulin appears to be an early target in aminoglycoside nephrotoxicity (15,16). A summary of some of our investigations on the effects of aminoglycosides on renal filtration, reabsorption and catabolism of proteins are presented herein.

Glomerular Alterations

Decreased GFR is a common finding in patients and experimental animals treated with aminoglycosides. Treatment of male rats with a toxic dose (30 mg/kg/day) of aminoglycosides for 7, 14 and 21 days (Fig. 1) demonstrated that only gentamicin and netilmicin decreased GFR over the entire treatment period. The same in vivo experiments indicate that tobramycin failed to decrease GFR. After 14 days of treatment GFR showed a tendency to return to control in rats treated with netilmicin. No recovery of GFR was observed in gentamicin-treated rats. Gentamicin treatment of Munich-Wistar rats for 10 days at a similar
dose (40 mg/kg/day) also induced a significant decrease in glomerular capillary ultrafiltration coefficient ($K_f$) (12).

Since aminoglycoside treatment appeared to decrease tubular reabsorption of the low molecular weight protein lysozyme, investigation of the effects of aminoglycosides on glomerular filtration of this protein was necessary to elucidate the mechanism by which aminoglycosides alter its renal reabsorption and catabolism. Thus, experiments with the isolated perfused kidney were designed to determine the glomerular sieving coefficient of lysozyme. At complete inhibition of tubular reabsorption of lysozyme the ratio of lysozyme clearance/inulin clearance ($C_{LY}/GFR$) expresses the glomerular sieving coefficient of lysozyme ($GS_{LY}$). Following aminoglycoside treatment, sodium iodoacetate was added to the perfusate (3–5 mM) to completely inhibit tubular reabsorption of lysozyme (17). Aminoglycoside treatment decreased the $GS_{LY}$ from a control value of 0.8 to 0.6 and 0.5 in kidneys from

**Table 1. Effect of aminoglycosides on the density of endothelial fenestrae (EF).**

| Treatment       | EF density (25 cm$^2$)$^a$ | % of Control |
|-----------------|-----------------------------|--------------|
| Saline (Control)| 99 ± 2 ($n = 4$)             | 100          |
| Netilmicin      | 103 ± 2 ($n = 4$)            | 100          |
| Gentamicin      | 82 ± 3* ($n = 5$)            | 82*          |
| Tobramycin      | 77 ± 3* ($n = 5$)            | 77*          |

$^a$The density of endothelial fenestrae was determined by counting the number of fenestrae on a 25 cm$^2$ area of prints from scanning electron microscopy. Each aminoglycoside was administered at a dose of 30 mg/kg/day for 7 days. Data are given as means $\bar{X} \pm$ SD. Numbers in parentheses represent the number of rats.

$^*_{\text{Significantly different from control value (p < 0.05).}}$
FIGURE 3. Effect of gentamicin on glomerular ultrastructure. Transmission electron micrograph of the afferent arteriole of juxtamedullary apparatus from (a) control and (b) gentamicin-treated rats for 7 days (30 mg/kg/day). Myoepithelioid cells (ME) contain numerous electron dense cytoplasmic granules (arrows) in control rats while these granules are almost completely depleted in gentamicin-treated rats. × 5470.
gentamicin- and tobramycin-treated rats, respectively; netilmicin had no effect. Scanning and transmission electron microscopy indicated that gentamicin and tobramycin altered the ultrastructure of the glomerular endothelium by reducing diameter and frequency of endothelial fenestræ (Fig. 2 and Table 1). Quantitative morphometric studies using data from scanning electron microscopy (Table 1) supported previous studies (18) and demonstrate that aminoglycoside treatment decreased the number of glomerular capillary endothelial fenestræ.

Glomerular functional and ultrastructural alterations caused by aminoglycoside treatment could be induced through a tubuloglomerular feedback mechanism mediated by the renin–angiotensin system which has been suggested to be related to the pathogenesis of acute renal failure by Thurau et al. (19). Consistent with this hypothesis, high doses of gentamicin (120 mg/kg/day) produced a significant increase in plasma renin activity and a concurrent decrease in GFR in rats (20). Lower doses of gentamicin or tobramycin (30 mg/kg/day) induced an almost complete depletion of cytoplasmic granules from the myoepithelial cells in the afferent arterial wall of the juxtaglomerular apparatus as revealed by transmission electron microscopy (Fig. 3). At the same dose, depletion of cytoplasmic granules was less severe in netilmicin-treated rats. However, in these studies, there was no disintegration of the granules, elevated exocytotic excretion processes, or activation of rough endoplasmic reticulum. Thus, it is uncertain whether the depletion of the cytoplasmic granules from the myoepithelial cells after aminoglycoside treatment was related to activation of the renin–angiotensin system. The precise role played by this system in aminoglycoside-induced renal failure remains to be clarified by further studies.

**Impairment of Tubular Reabsorption**

Treatment of patients or experimental animals with aminoglycoside antibiotics results in tubular cell injury and necrosis accompanied by enhanced excretion of glucose (21) or of LMWP such as β₂-microglobulin (16). These functional alterations suggest an impairment of tubular reabsorptive capacity. Indeed, increased urinary excretion of sodium and potassium are found in aminoglycoside-treated rats (Fig. 4). In these experiments gentamicin appeared to have a much more pronounced effect than netilmicin. The specific mechanism by which aminoglycosides decrease tubular reabsorption of electrolytes is still unknown.

Aminoglycoside treatment leads to an increased excretion of brush border enzymes (22), lysosomal enzymes (23) and LMWP such as β₂-microglobulin and lysozyme (16). Aminoglycoside-induced functional alterations were detected by measuring the urinary excretion of the LMWP lysozyme, the lysosomal enzyme N-acetyl-β-D-glucosaminidase and total proteins in intact rats (Table 2). Gentamicin was more potent than netilmicin in decreasing tubular reabsorption of lysozyme and induced damage to cellular membranes causing leakage of the lysosomal marker enzyme NAG and an increase in total protein excretion (Table 2). Tubular reabsorption of lysozyme had a tendency to return toward control despite continued administration of gentamicin or tobramycin (15). Determination of the glomerular sieving coefficient of lysozyme after aminoglycoside treatment allowed a more accurate quantitation of tubular reabsorption of lysozyme (Table 3). Gentamicin and tobramycin (30 mg/kg/day) decreased endocytic reabsorption of lysozyme in isolated perfused kidneys to about 50% after 7 days of treatment. Since aminoglycosides and lysozyme are taken up into tubular

---

**Table 2. Daily urinary excretion of endogenous lysozyme (LY), N-acetyl-β-D-glucosaminidase (NAG) and total protein (P) in aminoglycoside-treated rats.**

|                | Control     | Netilmicin | Gentamicin |
|----------------|-------------|------------|------------|
| Ly, μg/day     | 4.72 ± 0.50 | 5.95 ± 1.42| 31.79 ± 18.99 |
| NAG, mmole/hr  | 0.79 ± 0.08 | 0.78 ± 0.26 | 3.32 ± 1.76  |
| P, mg/day      | 6.22 ± 1.10 | 6.39 ± 0.38 | 38.3 ± 9.64  |

*All experimental data are given as mean value ± SD. Each experimental group consisted of five rats. Each aminoglycoside was administered at a dose of 30 mg/kg/day for 7 days.

*Data are significantly different from control (p < 0.05).*

**Table 3. Effect of aminoglycosides on renal reabsorption of lysozyme by the isolated perfused rat kidney.**

|                | Control     | Netilmicin | Gentamicin | Tobramycin |
|----------------|-------------|------------|------------|------------|
| X ± SD         | 71.7 ± 3.0  | 69.7 ± 3.5 | 35.4 ± 6.8 | 32.4 ± 10.5 |
| n              | 5           | 6          | 5          | 5          |

*Each aminoglycoside was administered at a dose of 30 mg/kg/day for 7 days. Lysozyme reabsorption is expressed as % of filtered load. n = number of kidneys.

*Significantly different from control (p < 0.05).*

---

**Figure 4.** Effects of aminoglycosides on electrolyte excretion in intact rats. Excretion of sodium and potassium in control and aminoglycoside-treated rats for 7 days (30 mg/kg/day). C = control, G = gentamicin, K = kanamycin, N = netilmicin. From Cojocel and Hook (24). Reprinted with permission of Elsevier Science Publishers, B. V., Amsterdam.
cells by endocytosis, it is very likely that the differential
effects of aminoglycosides on tubular reabsorption of
lysozyme represent specific alterations in proximal
tubular function such as impairment of the endocytic
protein reabsorption.

Decrease of Lysosomal Proteolysis

Protein degradation in the kidney occurs mainly in
lysosomes, organelles that are known to accumulate
nephrotoxicants such as aminoglycosides. Gentamicin
liberates the lysosomal membrane causing increased
release of lysosomal marker enzymes to the incubation
medium in vitro (24) and increased excretion of
lysosomal enzymes in vivo (25). Likewise, gentamicin
treatment of rats led to a decrease of lysosomal protein
degradation by renal cortical slices in a dose-related
fashion (26) (Fig. 5). In these studies, the effects of
gentamicin on lysosomal degradation of lysozyme by
renal cortical slices was measured as free (nonpre-
cipitable) radioactivity and was expressed as percentage
of total radioactivity released to the incubation medium.
The effects of gentamicin, tobramycin and netilmicin on
renal protein degradation were compared (Fig. 5) in the
isolated perfused rat kidney (8). In these studies
lysozyme degradation was estimated by the release of
tyrosine into the perfusate during a 150-min perfusion
period. Tyrosine concentration in the perfusate was
quantified by high-pressure liquid chromatography
(HPLC). The more nephrotoxic aminoglycosides, genta-
icin and tobramycin, significantly decreased the
release of tyrosine to the perfusate from a control
value of 12.0 to approximately 4.5 μmole. Netilmicin
appeared to have no effect on renal degradation of
lysozyme (Fig. 6). This study also showed that genta-
icin and tobramycin had similar effects on renal protein
catabolism. The decrease in renal catabolism of lyso-
zyme may be due indirectly to decreases in glomerular
filtration rate, the glomerular sieving coefficient of
lysozyme, and impairment of tubular endocytic uptake
of lysozyme. The direct effect of aminoglycosides on
lysosomal protein degradation may be due to an in-
crease in intralysosomal pH and subsequent decrease in
the activity of proteolytic enzymes. Treatment of rats
with gentamicin decreased the lysosomal activity of
cathepsin B (11), a proteolytic enzyme responsible for
the lysosomal breakdown of egg white lysozyme (27).

Acute Effects of Gentamicin

Cationic LMWP such as lysozyme and cytochrome c
compete for anionic binding sites at the proximal tubule
brush border, the first step in endocytic tubular
reabsorption (1,28,29). Similar competition between
cationic aminoglycosides appears to take place in
the processes of binding to the brush border (2) and subsequent renal accumulation (30). Since renal absorption of lysozyme takes place via endocytosis (31), the pharmacological interaction between lysozyme and gentamicin molecules in the early time after gentamicin infusion is very likely to affect tubular reabsorption and intracellular catabolism of lysozyme in the absence of tubular damage.

Isolated rat kidneys were perfused with gentamicin at concentrations of 0.25, 0.50, 1.0 and 2.5 mg/mL. A dose-dependent decrease in percentage reabsorption of lysozyme (Fig. 7) showed that gentamicin inhibits tubular reabsorption of lysozyme in a dose-dependent manner (32). Renal catabolism of $^{125}$I-lysozyme to smaller degradation products was measured as non-precipitable radioactivity ($^{125}$I and $^{125}$I-monoiodotyrosine) released to the perfusate. Perfusion of the kidneys at a perfusate concentration of gentamicin of 0.5 mg/mL and higher induced almost complete inhibition of renal degradation of lysozyme (Fig. 8). This inhibition could be due primarily to inhibition of tubular reabsorption of lysozyme by gentamicin (Fig. 7) and additionally to the inhibition of enzymatic activity of lysosomal proteases responsible for the lysosomal catabolism of lysozyme.

In summary, aminoglycosides act as nephrotoxicants at the glomerulus, by reducing the glomerular filtration of insulin and cationic proteins, at the tubule by inhibiting the endocytic reabsorption, and at the lysosome, by decreasing the proteolytic activity of lysosomal enzymes.

We gratefully acknowledge the assistance of Diane Hummel and Janet Dingerdissen in preparing the manuscript.

REFERENCES

1. Just, M., Erdmann, G., and Habermann, E. The renal handling of polybasic drugs. I. Gentamicin and aprotinin in intact animals. Naunyn-Schmiedeberg's Arch. Pharmacol. 300: 57–66 (1979).
2. Sastrasinh, M., Knau, T. C., Weinberg, J. M., and Humes, H. D. Identification of the aminoglycoside binding site in rat renal brush border membranes. J. Pharmacol. Exp. Therap. 222: 350–358 (1982).
3. Silverblatt, F. J., and Kuehn, C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 15: 335–345 (1979).
4. Bennett, W. M., Plamp, C. E., Elliott, W. C. Parker, R. A., and Porter, G. A., Effect of basic aminocids and aminoglycosides on $^3$H-gentamicin uptake in cortical slices of rat and human kidney. J. Lab. Clin. Med. 99: 156–162 (1982).
5. Collier, V. L., Lietman, P. S., and Mitch, W. E. Evidence for luminal uptake of gentamicin in the perfused rat kidney. J. Pharmacol. Exp. Therap. 210: 247–251 (1979).
6. Chahwala, S. B., and Harper, E. S. An investigation of the effects of aminoglycoside antibiotics on Na$^+$, K$^+$. ATPase as a possible mechanism of toxicity. Res. Comm. Chem. Pathol. Pharmacol. 35: 69–78 (1979).
7. Weinberg, J. M., Simmons, C. F., Jr., and Humes, H. D. Alterations of mitochondrial respiration induced by aminoglycoside antibiotics. Res. Comm. Chem. Pathol. Pharmacol. 27: 521–531 (1980).
8. Cojocel, C., Dociu, N., Maita, K., Sleight, S. D., and Hook, J. B. Effects of aminoglycosides on glomerular permeability, tubular reabsorption, and intracellular catabolism of the cationic low-molecular-weight protein lysozyme. Toxicol. Appl. Pharmacol. 68: 96–109 (1983).
9. Feldman, S., Wang, M.-Y., and Kaloyanides, G. J. Aminoglycosides induce a phospholipidosis in the renal cortex of the rat: an early manifestation of nephrotoxicity. J. Pharmacol. Exp. Therap. 220: 514–520 (1982).
10. Hostetler, K. Y., and Hall, L. B. Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity. Proc. Natl. Acad. Sci. (U.S.) 79: 1663–1667 (1982).
11. Morin, J. P., Viotte, G., Vandewalle, A., Van Hoof, F., Tulkens, P., and Fillastre, J. P. Gentamicin-induced nephrotoxicity: a cell biology approach. Kidney Int. 18: 588–590 (1980).
12. Baylis, C., Rennke, H. R., and Brenner, B. M. Mechanism of the defect in glomerular ultrafiltration associated with gentamicin administration. Kidney Int. 12: 344–353 (1977).
13. Luft, F. C., Aronoff, G. R., Evans, E. F., Connors, B. A., Weinberger, M. H., and Kleit, S. A. The renin-angiotensin system
in aminoglycoside-induced acute-renal failure. J. Pharmacol. Exp. Therap. 229: 433–439 (1982).

14. Schor, N., Ichikawa, I., Rennke, H. G., Troy, J. L., and Brenner, B. M. Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int. 19: 288–296 (1981).

15. Cojocel, C., and Hook, J. B. Differential effect of aminoglycoside treatment on glomerular filtration and renal absorption of lysozyme in rats. Toxiconology 22: 261–267 (1981).

16. Nicot, G., Merle, L., Valette, J. -P., Charmes, J. -P., and Lachatre, G. Gentamicin and sisomicin-induced renal tubular damage. Eur. J. Clin. Pharmacol. 23: 161–166 (1982).

17. Maack, T. Renal handling of low molecular weight proteins. Am. J. Med. 58: 57–64 (1975).

18. Luft, F. C., Aronoff, G. R., Evan, A. P., and Connors, B. A. The effect of aminoglycosides on glomerular endothelium: a comparative study. Res. Comm. Chem. Pathol. Pharmacol. 34: 89–95 (1981).

19. Thurau, K., and Boylan, J. W. Acute renal success. The unexpected logic oliguria in acute renal failure. Am. J. Med. 61: 308–315 (1976).

20. Luft, F. C., and Evan, A. P. Glomerular filtration barrier in aminoglycoside-induced nephrotoxic acute renal failure. Renal Physiol. (Basel) 3: 265–271 (1980).

21. Ginsburg, D. S., Quintanilla, A. F., and Levin, M. Renal glycosuria due to gentamicin in rabbits. J. Infect. Dis. 134: 119–122 (1976).

22. Mondorf, A. W., Ziegelmann, M., Klose, J., Hendus, J., and Breier, J. Comparative studies on the action of aminoglycosides and cephalosporins on the proximal tubule of the human kidney. J. Antimicrob. Chemother. 4(Suppl. A): 53–57 (1978).

23. Naruse, T., Hirokawa, N., Oike, S., and Maekawa, T. Clinical evaluation of urinary N-acetyl-β-D-glucosaminidase activity in patients receiving aminoglycoside and cephalosporin drugs. Res. Comm. Chem. Pathol. Pharmacol. 31: 313–320 (1981).

24. Violette, G., Morin, J. P., Godin, M., and Fillastre, J. P. Changes in the renal function of rats treated with cephoxin and a comparison with other cephalosporins and gentamicin. J. Antimicrob. Chemother. 7: 537–550 (1981).

25. Gibey, R., Dupond, J. -L., Alber, D., Lecomte des Floris, R., and Henry, J. -C. Predictive value of urinary N-acetyl-β-D-glucosaminidase (NG), alanineaminopeptidase (AAP) and β-2-microglobulin (β2M) in evaluating nephrotoxicity of gentamicin. Clin. Chem. Acta 116: 24–34 (1981).

26. Cojocel, C., Smith, J. H., Maita, K., Sleight, S. D., and Hook, J. B. Renal protein degradation: a biochemical target of specific nephrotoxicants. Fundam. Appl. Toxicol. 3: 278–284 (1983).

27. Yuzuriha, T., Katayama, K., and Fujita, T. Studies on bio-transformation of lysozyme. III. Comparative studies on bio-transformation on exogenous and endogenous lysozyme in rats. Biochim. Biophys. Acta 490: 235–246 (1977).

28. Cojocel, C., Franzen-Sievèking, M., Beckmann, G., and Baumann, K. Inhibition of renal accumulation of lysozyme (basic low molecular weight protein) by basic proteins and other basic substances. Pflugers Arch. 380: 211–215 (1981).

29. Sumptio, B. E., and Maack, T. Kinetics, competition, and selectivity of tubular absorption of proteins. Am. J. Physiol. 243: F379–F392 (1982).

30. Kuo, C. H., and Hook, J. B. Specificity of gentamicin accumulation by rat renal cortex. Life Sci. 25: 875–878 (1979).

31. Christensen, E. I., and Maunsbach, A. B. Intralysosomosal digestion of lysozyme in renal proximal tubule cells. Kidney Int. 6: 396–407 (1974).

32. Cojocel, C., and Hook, J. B. Effects of acute exposure to gentamicin on renal handling of proteins. Toxicology 28: 347–356 (1983).

33. Cojocel, C., and Hook, J. B. Aminoglycoside nephrotoxicity. Trends Pharmacol. Sci. 4(4): 174–179 (1983).